BI-2493 is a structural analogue of BI-2865 and a highly selective pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research.

Lipid C12-A1 is an ionizable lipid. C12-A1-LPN is a potent and safe LNP platform to deliver Foxp3 mRNA to CD4+ T cells to engineer immunosuppressive FP3T cells. C12-A1 has a slightly lower average cell viability than C14-A1.

Lipid 2-10 is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure.

RCS-03-104-4 is a cysteine-reactive JQ1 analogue, which potently induces BRD4 degradation with DC50 and Dmax of 79 nM and 71%, respectively. RCS-03-104-4 causes BRD4 degradation by inducing its proximity with the ubiquitin ligase activity of DCAF11.

RCB-4-8 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA.1 RCB-4-8-containing LNPs improve lung transfection efficiency by approximately 100-fold over MC3-containing LNPs in mice.

IR-19-Py(A20-0l) is an ionizable, degradable lipid for nebulized mRNA delivery.

IR-117-17(A10-LIN) is an ionizable, degradable lipid for nebulized mRNA delivery. Nebulized IR-117-17 LNPs produced a 300-fold improvement in lung mRNA delivery over the top previously described LNP. and a two-fold improvement over the previously reported PBAE, including up to a 45-fold improvement in delivery to the large airways.

BODIPY 581/591 C11 is a BODIPY borofluoroprene derivative with good light stability and low fluorescence artifacts. BODIPY 581/591 C11 can be used for study lipid peroxidation and antioxidant properties in living cells, or detect ferroptosis by reaction with hydroxyl radicals. BODIPY 581/591 C11 is emitted at 591 nm (reduced prototype), or redshifted to 510 nm (oxidized type). The excitation wavelengths were 581 nm (reduced prototype) and 500 nm (oxidized type).

Sotuletinib, also known as BLZ945, is a potent and selective CSF-1R kinase inhibitor. BLZ945 showed effects of CSF1R inhibition on other tumor-infiltrating immune cells. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas. BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 prevents tumor progression in the keratin 14-expressing human papillomavirus type 16 (K14-HPV-16) transgenic model of cervical carcinogenesis.

Koenimbine is an anticancer agent that can be obtained from the leaves and fruits of Murraya koenigii. Koenimbine can induce apoptosis and necrosis in HT-29 and SW48 cells. Koenimbine can be used in the research of cancer.

Perlolyrin (Tribulusterine) is an alkaloid that can be isolated from dried fruits of Tribulus terrestris.

PK-10 is a synergistic antibacterial agent of Fluconazole.

SKF 91488 (Homodimaprit) dihydrochloride is a potent and noncompetitive histamine N-methyltransferase inhibitor with a Ki value of 0.9 microM. SKF 91488 dihydrochloride inhibits the methylation of labeled histamine in mice.

CTL-06 is an inhibitor of Fatty Acid Synthase (FASN).

CBiPES hydrochloride is a mGlu2 receptor positive allosteric modulator (EC50: 92.8 nM). CBiPES hydrochloride attenuates stress-induced hyperthermia and PCP-induced hyperlocomotor activity. CBiPES hydrochloride can be used for research of neurological disease.

TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects.

F7H is a Frizzled receptor FZD7 antagonist (IC50: 1.25 μM). Frizzled receptors (FZDs) influence Wnt signaling, mediating embryonic development and tissue homeostasis. F7H is a potent ligand for the FZD7 transmembrane domain (TMD).

COH1 is a ribonucleotide reductase (RR) inhibitor. COH1 can be used in research into cancer, mitochondrial diseases, and neurodegenerative diseases.

BML-278 is an activator of sirtuin 1 (SIRT1) that has an EC150 value (effective concentration able to increase the enzyme by 150%) of 1 µM.

CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles.

A novel and seletive HDAC6 inhibitor.

4A3-SCC-10 is a biodegradable ionizable lipid with superior endosomal escape and rapid mRNA release ability. In comparison with DLin-MC3-DMA, 4A3-SCC-10-formulated LNPs significantly improve mRNA delivery in livers by 87-fold.

4A3-SCC-PH is a biodegradable ionizable lipid with superior endosomal escape and rapid mRNA release ability. In comparison with DLin-MC3-DMA, 4A3-SCC-PH-formulated LNPs significantly improve mRNA delivery in livers by 176-fold. 4A3-SCC-PH enhance Fluc mRNA release and luciferase expression in tumor cells, further assisting cancer metastasis delineation and surgical resection.

Mal-propyl-Ala-Ala-Asn(Trt)-PAB is a hetero bifunctional cross-linker, useful in antibody drug conjugation (ADC).

Sialylglycopeptide is a complex N-glycan, bearing a short peptide fragment. Sialylglycopeptide, as a starting material for the semi-synthesis of N-glycans, can be used for various researches.

IAG933 (IAG-933) is a potent, selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor (YAP/TAZ-TEADs PPI), inhibits TEAD-driven transcriptional activity and displays anti-cancer effects.

DFHBI-1T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=472 nm/507 nm). DFHBI-1T binds to RNA aptamers (Spinach, Spinach2, iSpinach, and Broccoli) and causes specific fluorescence and lower background fluorescence. DFHBI-1T is used to image RNA in live cells.

DFAME is a red fluorophore (Ex=508 nm, Em=641 nm). Beetroot and Corn are dimeric fluorogenic RNA aptamers that can bind to DFAME to form Beetroot-DFAME (Kd=460nM) and Corn-DFAME (Kd= 3600nM). Beetroot-DFAME (Kd=460nM) and Corn-DFAME can be used to form RNA assemblies in living cells. Creating RNA assemblies can be used for the study of RNA Nanostructures. DNA/RNA Nanostructures would be useful in cell and gene therapy (CGT) research.

L-369 (Lipid 369,L369) is novel class of ionizable lipid for siRNA delivery with improved in vivo elimination profile with excellent translation across species,including NHP, wide safety margin.

Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a glucagon-like peptide-1 (GLP-1R)/glucagon receptor GCGR co-agonist. Mazdutide has safety and tolerability, and it can be used for research in obesity and type 2 diabetes (T2D).

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Iso-A11B5C1 is an ionizable lipid. The iso-A11B5C1 LNP demonstrates a high level of muscle-specific mRNA delivery efficiency. exhibiting transfection efficiency comparable to the commercially available lipid SM-102, while considerably reducing inadvertent mRNA expression in main organs such as the liver and spleen.Additionally, study results show that intramuscular administration of mRNA formulated with iso-A11B5C1 LNP caused potent cellular immune responses, even with limited expression observed in lymph nodes.

RLY-2608 is an oral allosteric pan-mutant isoform-selective PI3K伪 inhibitor that was discovered using MD modeling and cryo-EM to identify allosteric networks and opportunities for small molecules, followed by DEL screening.

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

Pelcitoclax, also known as APG 1252 and BM1251, is a potent and selective Bcl-2/Bcl-XL inhibitor. APG-1252 A Bcl-2 homology (BH)-3 mimetic and selective inhibitor of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL, with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2/Bcl-XL inhibitor APG-1252 specifically binds to and inhibits the activity of the pro-survival proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells.

AM-2-19 (SF001) is an ergosterol-extracting polyene antifungal that is discovered through modifications to the amphotericin B toxin by chemists.

INX-315 is a novel and potent CDK2 inhibitor with IC50 of 2.3 nM and shows high selectivity over other CDK family members (374 nM against CDK1/cyclin and 950 nM against CDK9/cyclin,respectively). INX-315 promotes retinoblastoma protein hypo-phosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, overcomes breast cancer resistance to CDK4/6i and delays the onset of CDK4/6i resistance in breast cancer.

TRIM-473 is a novel ligand for the PRY-SPRY domain of the E3 RING ligase TRIM58 with EC50 of 5.3 μM.

Compoud 18 (AEP inhibitor) is first orthosteric, selective, orally bioavailable, and brain penetrant inhibitor with IC50 of 7.8 nM against asparagine endopeptidase (AEP) with an irreversible binding mode.

ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).

 ABBV-467 is a selective MCL-1 inhibitor. In vivo, intermittent dosing of ABBV-467 as monotherapy or in combination with venetoclax inhibits the growth of xenografts from human hematologic cancers.

BMS-502 is a dual DGKα and ζ inhibitor. BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program.

Pociredir is an embryonic ectoderm development (EED) protein inhibitor. Pociredir can be used for the research of inflammatory or hemoglobinopathies, such as sickle cell disease.

TP0472993 is an oral 20-hydroxyeicosatetraenoic acid synthesis inhibitor

CT-3 is an irreversible trypanosomal topo. II inhibitor.

 GNE-7883 is a pan-TEAD inhibitor.

KCL-286 is an oral RARβ agonist.

AEF0117 is a Signaling-specific CB1 inhibitor.

LUNA18 is an 11-mer cyclic peptide inhibitor for the intracellular tough target RAS with Kd (KRAS/G12D) of 0.043 nM and cellular IC50 of 1.4 nM (AsPC-1). LUNA18 orally and dose-dependently exhibits potent anti-cancer activities in a mouse xenograft model. LUNA18 shows 21–47% oral bioavailability in animals such as mouse, rat, monkey, and dog and notably does not require special formulations.

DNL343 is a potent, selective, and brain-penetrant eukaryotic translation initiation factor 2B (eIF2B) activator with ATF4 IC50 of 9.8 nM.

LY3473329 (Muvalaplin) is a potent, multivalent disruptor of lipoprotein(a) (Lp(a)). LY3473329-HCl binds to apolipoprotein KIV8 selectively with a potency of 22 nM and inhibits the formation of Lp(a) particles in vitro with IC50 of 0.09 nM.

NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.

Suzetrigine is a SCN10A blocker. The SCN10A is associated with the onset of pain due to peripheral neuropathy. Suzetrigine functions as an analgesic.

BMS-986172 is a highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a L BMS-986172 showed on-target- and mechanism-based pharmacology. Moreover, its favorable pharmacokinetic (PK) profile and the lack of species variability in the glucuronidation potential resulted in a greater confidence level in the projection of a low dose for achieving targeted efficacious exposures in humans. Consistent with these projections.

Encaleret, also known as JIT-305, is an oral calcium-sensing receptor (CaSR) antagonist, for the treatment of osteoporosis.

PF-07202954 is a DGAT2 Inhibitor (IC50 = 10 nM) with Longer Predicted Half-Life.

NT-0796 is a Brain-Penetrant and Highly Potent. NLRP3 Inflammasome Inhibitor (IC50 = 0.32 nM) for Neuroinflammatory Disorders.

STM3006 is a highly potent, selective and orally active METTL3 inhibitor. STM3006 can be used for the research of acute myeloid leukaemia (AML).

Zosurabalpin (RG6006) is a class of tethered macrocyclic peptide (MCP) antibiotic. Zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB (carbapenem-resistant acinetobacter baumannii) both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms.

NC-TNP (noncationic thiourea lipids nanoparticles) could compress mRNA by strong hydrogen bonds interaction between thiourea groups of NC-TNP and the phosphate groups of mRNA. NC-TNP could escape the recycling pathway to inhibit the egress of internalized nanoparticles from the intracellular compartment to the extracellular milieu. NC-TNP-encapsulated mRNA shows higher gene transfection efficiency in vitro and in vivo than mRNA-LNP formulation. NC-TNP also shows spleen targeting delivery ability with higher accumulation ratio (spleen/liver), compared with traditional LNP.

TAK-994 is an oral, selective OX2R agonist developed by Takeda for the treatment of narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). The molecule follows Takeda’s previous clinical molecule, TAK-925 (danavorexton), which was the first OX2R agonist to be tested in people with NT1 but had poor oral bioavailability and was administered intravenously in the clinic.

RAS Inhibitor A122 - This oral tri-complex RAS(MULTI)(ON) inhibitor is a relative from a patent application of the currently undisclosed RMC-6236, which is currently in Phase I/Ib clinical trials for solid tumors. The RAS(MULTI) series was identified via SBDD based on extensive knowledge of RAS tricomplex inhibitors such as G12C tricomplex inhibitor, RMC-6291.

KIO-301 – A photoswitchable HCN channel blocker with positive initial results from a Phase I/II for retinitis pigmentosa and choroideremia study that is being developed by KIORA Therapeutics.

PS-13 precursor 19 is the precursor of PS-13. PS13 is a highly potent COX-1 inhibitor (IC50=1 nM) and 1,000 times more selective for COX-1 than COX-2 (7).

PS13 is a highly potent COX-1 inhibitor (IC50=1 nM) and 1,000 times more selective for COX-1 than COX-2 (7). In non-human primates, 11C-PS13 showed selective binding to COX-1 over COX-2 in most major organs including the spleen, gastrointestinal tract, kidneys, and brain.

SK-575 is a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations and induces potent and specific degradation of PARP1 in various human cancer cells even at low picomolar concentrations. SK-575 achieves durable tumor growth inhibition in mice when used as a single agent or in combination with cytotoxic agents, such as temozolomide and cisplatin.

NP3-562 is a potent, orally bioavailable, tricyclic NLRP3 inhibitor with IC50 of 0.26 μM in the FP binding assay. NP3-562 demonstrates excellent potency in human whole blood and full inhibition of IL-1β release in a mouse acute peritonitis model.

TL 13-27 is a negative control for TL 12-186. Demonstrates no kinase degradation in vitro.

DSPE-MPEG(5000) is a PEGylated form of 1,2-distearoyl-rac-glycero-3-PE (DSPE). It has been used in the synthesis of lipid nanoparticles (LNPs) and liposomes for in vitro and in vivo two-photon bioimaging.

RGT1383 is a novel GLP-1R agonist, an analog of PF-06882961.

Inhibitor of VMAT-2, decreasing monamines into synaptic vesicles

5-alpha-hydroxy-laxogenin is a derivative of the spirostane-type steroid, laxogenin. 5α-Hydroxy-laxogenin can be used as a plant-based anabolic agent as a dietary supplement.

5-HT3 antagonist 4 is a 5-HT3 receptor (5HT3R) antagonist. 5-HT3 antagonist 4 prevents diabetes-induced depressive phenotypes in mice.

Selective inhibitor of ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs 5 or aggrecanase-2)

ALK-001 is a vitamin A analog potentially for the treatment of Stargardt’s disease.

Novel Enrichable and MS-Cleavable Cross-linker to Define Protein-Protein Interactions by Mass Spectrometry

Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib, a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research.

AP1510 is a potent cell-permeable ligand for human FKBP12. AP1510 regulates protein-protein interactions through dimerization.

aTAG 4531 (CFT-4531) is a potent, selective, and onmechanism tool degrader of MTH1 with DC50 value of 0.28 nM and Ki value of 1.8 nM. degradation activity is due to the intricate formation of the ternary complex between the MTH1 aTAG, CRBN E3 ligase, and aTAG tool degrader .

AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways.

Azide-A-DSBSO crosslinker is a mass spectrometry (MS)-cleavable, membrane-permeable, homobifunctional, azide-labeled, acid-cleavable cross-linked peptide. Azide-A-DSBSO crosslinker enables the study of protein-protein interactions via cross-linking mass spectrometry (XL-MS).

BB-83698 is a peptide deformylase inhibitor and potent antimicrobial with excellent activity against streptococci and Moraxella catarrhalis strains.

Novel, systemically active kynurenine aminotransferase 2 (KAT2) inhibitor, significantly decreased escape latency in the Morris water maze, indicating improved performance in spatial and contextual memorynovel

Novel selective inhibitor of RARγ

Novel RBP4 antagonist with good in vitro potency and selectivity and optimal rodent pharmacokinetic (PK) and pharmacodynamic (PD) characteristics

Bulgecin A is an inhibitor of binuclear metallo-beta-lactamases and Lytic transglycosolase.

Cell permeable derivative of calcein, becoming fluorescent on hydrolysis

(E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.

CGA-JK3 is CGA-JK3 is an ATP-competitive inhibitor of IKKβ-catalyzed kinase activity. CGA-JK3 inhibits IκBα phosphorylation in LPS (HY-D1056) - induced RAW 264.7 cells.

Blue fluorescent amino acid, exhibiting blue fluorescence (λ max ~ 405 nm) with a high quantum yield and long lifetime

Novel inhibitor of α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons, selectively interacting with Synaptotagmin 1

Lipophilic fluorescent reagent, labeling membranes and other hydrophobic structures

Highly potent cytotoxic microtubule inhibitor

Novel potent inhibitor of dihydroorotate dehydrogenase (DHODH)

Entasobulin is a β-tubulin polymerization inhibitor with potential anticancer activity.

GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies.

Novel LXR inverse agonist, functioning as LXR a degrader, significantly reducing LXR protein levels in PDAC cell lines

GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9).

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.

Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG

GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA.

HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.

JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.

L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively.

Novel selective agonist of the human melanocortin 1 receptor (hMC1R) for sunless tanning and prevention of genotoxicity of UV in melanocytes

Peroxisome proliferator-activated receptor-α/γ (PPAR α/γ) dual agonist

M4K2209 is a potent, selective BMP type I receptor ALK2 inhibitor with IC50 of 9 nM, >180-fold selective over ALK5 (IC50=2427 nM).

Neurokinin receptor antagonist with antiemetic activity

Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE)

Novel mc (maleimidocaproyl) linker plus MMAD (Monomethylauristatin D) to be used for prepare antibodies conjugates via cysteine-capped mechanism

Second generation papaverine analog, acting as an anticholinergic agent

Natural antifungal agent, significantly inducing lipid peroxidation, activating the antioxidant enzymes, and exhibiting effective activity against F. solani (EC50 = 10.56 µM)

mG2N001 is a potent negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) with IC50 of 93 nM.

Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis.

Nrf2-Activator is a potent Nrf-2 activator.

Specific inhibitor of vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF)

Agonist of sst2, sst3 and sst5 somatostatin receptors

Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential

Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis.

Selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6

Potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2)

PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders.

Novel, potent and specific inhibitor of sphingosine kinase-1 (SphK1)

Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects.

Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor

Novel potent and selective 5-HT2B receptor antagonist

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)

rac-NBI-74330 is a potent and selective CXCR3 antagonist.

Selective phosphodiesterase-4 (PDE4) inhibitor

SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action.

FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist.

Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease.

UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays.

Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent

Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals

VU0366248 is a mGlu5 negative allosteric modulator.

VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity.

Biricodar (VX-710) is a modulator of P-glycoprotein and MRP-1; shows effective chemosensitizing activity in multidrug resistant cells.

W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth.

YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice.

Novel Selective Degrader of GSPT1

Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.

VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM). VU0364739 decreases cancer cell proliferation.

RMC-6236 (Compound A122) is a potent RAS(ON)MULTI inhibitor and can be used for the research of cancer.

DPPE is a derivative of phosphatidylethanolamine with (16:0) palmitoyl acyl chains

DMPE is derivative of phosphatidylethanolamine with (14:0) myristic acid acyl chains.

mPEG-DMG, MW 5,000 is a large PEG lipid containing a DMG group and a methoxy cap. The methoxy cap is inert while the DMG group is a popular ligand for developing PEG-lipids and lipid nanoparticles more broadly. Varying the size of a PEG linker greatly impacts its molecular dynamics, thereby affecting DMPK and ADME properties of a given API.

1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant gonadal LPC (lysophosphatidylcholine).

1-Stearoyl-sn-glycero-3-phosphocholine is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (POPC), a phospholipid, is a major component of biological membranes. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC is used for the preparation of liposomes and studying the properties of lipid bilayers.

DMPG is a phospholipid containing the saturated long-chain (14:0) myristic acid.

DSPA is a form of phosphatidic acid (PA) containing a phosphatidic acid head group and 18:0 fatty acids

DOPG-Na is a phospholipid containing the long-chain (18:1) fatty acid oleic acid inserted at the sn-1 and sn-2 positions. It can be used in the generation of micelles, liposomes, and other artificial membranes. DOPG is an anionic phospholipid derivative. The negatively charged liposomes prepared with DOPG has been found to possess the best loading capacity and encapsulation rate for Peptide Nucleic Acid (PNA) oligomers.

DPhPC is a phospholipid used to synthesize bilayer vesicles. DPhPC bilayers do not permit ions to leak in the absence of a pore/ion channel, which can be used for studies on channel proteins.

DPPA is a form of phosphatidic acid (PA).

2-Oleoyl-1-stearoyl-sn-glycero-3-phosphocholine (1-Stearoyl-2-oleoyl-sn-glycero-3-PC) is an active compound. 2-Oleoyl-1-stearoyl-sn-glycero-3-phosphocholine can be used for various biochemical studies.

18:0-18:2 PE is a lipid for agents delivering. 18:0-18:2 PE is mainly composed of unsaturated fatty acids. 18:0-18:2 is considered important precursors of important odorants (IOs) in Eriocheir sinensis.

1-Stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine sodium is a glycerophospholipid.

DIM1 is a sugar-alcohol-derived ionizable lipid with mannitol as the precursor. DIM1T is an optimal LNP formulation for potent mRNA delivery in adipose stem cells (ASCs). Importantly, DIM1T LNPs demonstrated considerably higher mRNA delivery efficiency than MC3, ALC-0315, and SM102. The DIM1T LNP-SEC engineered ASCs (DS-ASCs) prolong expression of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 12 (CXCL12), which show superior wound healing efficacy over their wild-type and DIM1T LNP-mRNA counterparts in the diabetic cutaneous wound model.

CBI1 (covalent BAX inhibitor 1) is a compound that selectively derivatizes BAX at C126 with BME50 value of 905 μM. CBI1 inhibits BAX activation by triggering ligands or point mutagenesis.

POPE is a phospholipid, and can be used for drug delivery.

L-Dilinoleoyllecithin is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/18:2(9Z,12Z)), in particular, consists of two chains of linoleic acid at the C-1 and C-2 positions. The linoleic acid moieties are derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

DOTAP mesylate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Trilinolein is an endogenous metabolite.

14:0 PEG2000 PE (DMPE-PEG2000) is a PEG-phospholipid conjugate to prepare nanostructured lipid carrier.